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Abstract: The use of targeted inhibitors has shown promise as an effective approach in cancer therapy. However, targeted 
therapies based only on one drug, such as 17-allylamino-17-demethoxygeldanamycin (17-AAG), have limited success, partly 
because cancer cells engage alternate pathways for survival and proliferation. In the present study, we evaluated whether 
dehydroxymethylepoxyquinomicin (DHMEQ), a nuclear factor κB (NF-κB) inhibitor, can enhance the antitumor activities 
of 17-AAG, a 90 kDa heat shock protein (Hsp90) inhibitor, in the anaplastic thyroid cancer cell line KTC2. We examined the 
effect of combined drug treatment vs single drug treatment on cell survival. Isobologram analysis was performed to distin-
guish the additive vs synergistic effects of the drug combination. Western blotting was performed to investigate apoptosis 
markers: caspase 3, poly(ADP-ribose) polymerase-one (PARP-1), B-cell lymphoma-extra large (Bcl-XL), X-linked inhibitor 
of apoptosis (XIAP) and cellular inhibitor of apoptosis 2 (cIAP-2). Compared to monotherapy, the combined treatment 
enhanced growth-inhibitory effects in a synergistic manner and strongly potentiated apoptosis. These results demonstrate 
the first in vitro evidence that a combination of Hsp90 and NF-κB inhibitors is a more effective modality for inhibiting cell 
proliferation and survival in anaplastic thyroid carcinoma cells than either agent alone, warranting further investigations.
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INTRODUCTION
Anaplastic thyroid cancer (ATC) is a rare, undifferenti-
ated thyroid cancer, with a high malignant potential 
and poor prognosis. The five-year survival rate from 
this type of cancer is less than 5%, with most patients 
dying within 3 to 6 months of diagnosis despite con-
ventional multimodality treatment strategies, which 
include surgery, external beam radiotherapy and 
chemotherapy [1,2]. Treatment failure in ATC is often 
associated with resistance to chemotherapy drugs. Thus, 
there is a pressing need for more effective therapeutic 
approaches, such as those including targeted inhibi-
tors, specially when used in combination. Targeted 
inhibitors act on specific target molecules resulting in 
the inhibition of key signaling cascades in malignant 
tumor cells. Among the different classes of promising 
molecular targets for therapeutic purposes in ATC are 
heat shock proteins (HSP) and NF-κB [2].
Hsp90 functions as a molecular chaperone by 
binding to different cellular proteins (protein kinases, 
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transcription factors, etc.), and supporting their proper 
folding, stability and function. Many of these client 
proteins are involved in cell proliferation, differentia-
tion, invasion, metastasis and drug resistance and are 
thus frequently mutated or overexpressed in cancer. 
Intact Hsp90 chaperone function is what cancer cells 
are particularly dependent on, since inhibition of Hsp90 
leads to ubiquitin-proteasome degradation of its cli-
ent proteins. Moreover, enhanced Hsp90 affinity for 
mutated or functionally deregulated target proteins in 
cancer cells has been observed and documented. This 
explains why Hsp90, which is often overexpressed in 
cancer, plays a critical role in tumor cell growth and/
or survival [3-5]. Hsp90 operates as an ATP-binding 
system. The benzoquinone ansamycin antibiotic gel-
danamycin and its less toxic analog with improved 
bioavailability, 17-AAG, were found to inhibit Hsp90 
multi-chaperone complex formation by docking into 
the ATP-binding site in the N-terminal domain of this 
protein [6,7]. Although Hsp90 is expressed both in 
normal and tumor cells, it was determined that tumor 
cells harbor a finely-tuned Hsp90 fraction that exists 
in an altered conformation, with a 100-fold higher 
binding affinity for 17-AAG than Hsp90 derived from 
normal cells [8,9]. This, as well as the fact that Hsp90 
regulates multiple proteins involved in different pro-
cesses during cancer development and progression, 
makes it a unique anticancer target. Cytotoxic activities 
of 17-AAG were demonstrated in different thyroid 
cancer cell lines among others, including the anaplastic 
thyroid cancer cell lines ARO, FRO, ACT1, 8505C 
and CAL62 [10-13]. A number of phase I, II and III 
clinical trials of 17-AAG have been conducted so far, 
as summarized in [14]. Data from these clinical trials 
show that 17-AAG can be given safely at biologically 
active dosages, with mild toxicity. Although phase I 
and II clinical trials of 17-AAG as a single agent did 
not demonstrate considerable clinical efficiency, the 
combination of 17-AAG with other anticancer drugs 
showed more promise regarding the clinical benefit 
for cancer patients [14].
NF-κB is a ubiquitously expressed proinflammatory 
transcription factor that regulates the expression of a 
number of genes involved in inflammation as well as in 
cell proliferation, apoptosis, invasion, angiogenesis and 
metastasis. NF-κB is typically a heterodimer comprised 
of Rel family proteins p50 and p65. These dimers are 
usually located in the cytoplasm in an inactive form 
as a result of association with inhibitory factors, IκB 
proteins. A number of extracellular signals can lead 
to phosphorylation and degradation of IκB, resulting 
in NF-κB activation and translocation to the nucleus, 
where it binds to specific promoters and regulates 
target gene expression [15]. As an antiapoptotic fac-
tor, NF-κB is one of the major reasons of resistance to 
chemotherapy, and it crucially affects the outcomes of 
cancer treatments [16]. ATC often exhibits constitutive 
and strong activation of NF-κB, which is extensively 
correlated with resistance to therapy and the aggres-
siveness of ATC [17]. Furthermore, a recent study 
identified NF-κB signaling pathways to be among the 
key pathways that regulate cancer stem cell proper-
ties in ATC [18]. An NF-κB inhibitor – DHMEQ, a 
derivative of the antibiotic epoxyquinomicin C, has 
been found to inhibit tumor necrosis factor (TNF)-
induced activation of NF-κB by suppressing NF-κB 
nuclear translocation, thus promoting apoptosis in 
a variety of cancer cells [19-22], including anaplastic 
thyroid carcinoma cells [23]. 
The aim of this study was to determine whether 
the combined treatment with 17-AAG and DHMEQ 
displays improved antitumor activity over either agent 
alone in the anaplastic thyroid carcinoma cell line 
KTC2. To our knowledge, this is the first time that the 
combined effect of these two agents is investigated in 
the anaplastic thyroid carcinoma cells.
MATERIALS AND METHODS
Reagents
Both 17-AAG and DHMEQ were dissolved in 99.9% 
dimethyl sulfoxide (DMSO) (Wako Chemicals, Osaka, 
Japan) at stock concentrations of 1 mM and 10 mg/mL, 
respectively, and stored at -20°C. Primary antibodies 
were obtained from the following sources: Bcl-XL 
polyclonal antibody from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA); XIAP polyclonal antibody, 
PARP-1 polyclonal antibody, and cleaved caspase 3 
polyclonal antibody were all from Cell Signaling Tech-
nology (Danvers, MA, USA). The polyclonal antibody 
to cIAP-2 was from R&D Systems (Minneapolis, MN, 
USA). Secondary antibodies were obtained from Cell 
Signaling Technology (Danvers, MA, USA).
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Cell culture
The human anaplastic thyroid carcinoma cell line, 
KTC-2, derived from pleural effusion metastasis, with 
no TP53 mutation, was provided by the Department of 
Molecular Medicine, Medical School, Nagasaki Univer-
sity, Japan. Cells were grown in Roswell Park Memorial 
Institute (RPMI) 1640 medium supplemented with 
5% fetal bovine serum (FBS) and 1% (w/v) penicillin/
streptomycin in a 5% CO2 humidified atmosphere at 
37°C. Primary human thyroid cell culture was estab-
lished as described [24] and maintained in a Dulbecco’s 
Modified Eagle Medium (DMEM):F12 mixture (1:2) 
supplemented with 3% FBS and 1% (w/v) penicillin/
streptomycin [all reagents were obtained from Sigma 
(St. Louis, MO, USA)].
Cell survival assay 
Cell suspensions (100 μL, 3000 cells per well) were 
added to each well of 96-well plate flat-bottom mi-
crotiter plates (NalgeNunc International, Tokyo, Japan) 
in RPMI 1640 containing 5% FBS, and incubated for 
24 h before treatment. Solutions, in increasing con-
centrations ranging from 1 nM to 1 μM of 17-AAG 
and with DHMEQ at a dose range of 0.1 μg/mL to 
20 μg/mL, respectively, were added to each well in 
11 μL medium. The control wells contained DMSO 
at a final concentration of 0.1%. After incubation, a 
water-soluble tetrazolium salt (WST)-based assay was 
performed as follows: 10 μL of the cell counting kit 
solution (CCK-8, Dojin, Osaka, Japan) were added 
to each well and incubated for 1 h at 37°C. Optical 
densities were measured at 450 nm in a microplate 
reader. Thus, the drug concentrations of 100 nM of 
17-AAG and 2-10 μg/mL DHMEQ were determined 
as the most effective after 24, 48 and 72 h of treatment. 
Analysis of the combined drug effects
Drug synergy was determined by the combination-index 
and isobologram analyses. Briefly, the combination-
index (CI) is a quantitative representation of the degree 
of drug interaction calculated by the following equation 
(CI) = (D)1/(Dχ)1 + (D)2/(Dχ)2 using the CalcuSyn 
software (Biosoft, Ferguson, MO, USA) where (Dχ)1 
and (Dχ)2 are the concentrations of each drug alone, 
which exert χ% effect while (D)1 and (D)2 are the 
concentrations of drugs in combination, which elicit 
the same effect. The fraction affected (Fa) represents 
the fraction affected by a given drug concentration; 
the evolution of drug interactions can be assessed 
by the Fa-CI plot. On the basis of the dose-response 
curves obtained from the cell survival assay for KTC2 
treated with the inhibitors, alone or in combination, 
the CI values were generated over the range of fraction 
affected (Fa) levels from 5%-95% growth inhibition. 
Synergism, additivity and antagonism are defined as 
CI<1, CI=1 and CI>1, respectively [25].
Preparation of cell extracts and Western blot
After the indicated treatment duration, the treated cells 
were washed twice in an ice-cold phosphate-buffered 
saline (PBS), collected in 1 mL of PBS and centrifuged 
at 1000 ×g for 3 min. The pellets were resuspended in 
200 μL of lysis buffer (Cell Signaling Technology, Bev-
erly, MA, USA) containing protease and phosphatase 
inhibitors and incubated for 15 min on ice. Lysates were 
then centrifuged for 15 min at 25000 ×g at 4°C, and the 
supernatants were stored at -80°C. Protein concentra-
tions were determined with the bicinchoninic acid 
(BCA) assay kit (Sigma-Aldrich, St. Louis, MO, USA).
Western blotting analysis was performed accord-
ing to standard procedures as described previously 
[26]. Proteins were resolved by the sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE), transferred onto polyvinylidene difluoride 
(PVDF) membrane (Millipore, Bedford, MA, USA), and 
subjected to immunoblotting with appropriate primary 
and secondary antibodies. The antigen-antibody com-
plexes were visualized using chemiluminescent reagents 
(Amersham, Arlington Height, IL, USA). Densitometry 
analysis was performed using ImageJ software [27].
RESULTS
Cytotoxic effects of 17-AAG and DHMEQ in 
anaplastic thyroid carcinoma cells
The combined treatment of 17-AAG and DHMEQ 
strongly enhanced the growth-inhibitory effect in 
KTC2 cells compared to each single drug treatment. 
This effect was already evident after 24 h of treatment, 
as shown in Fig. 1A. The inhibitory effect was increased 
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even more after 48 h of treatment (Fig. 1B) and by 
72 h, no cells survived at any of the 4 indicated dose 
combinations (data not shown). In contrast, cultured 
primary thyrocytes showed substantially lower sensitiv-
ity to combined treatment, and no significant effect on 
primary cell survival was observed until the DHMEQ 
dose was increased to 10 μg/mL (Fig. 1C and 1D).
17-AAG and DHMEQ combined drug effect
The combination index method showed a synergistic 
antiproliferation effect of 17-AAG and DHMEQ in 
KTC2 cells, which was observed at all 4 dose combi-
nations (Fig. 2).
Apoptotic changes in 17-AAG and DHMEQ 
treated thyroid cancer cells
Immunoblot analysis showed that the combined treat-
ment triggered the cleavage of proapoptotic molecules, 
caspase 3 and PARP-1, in KTC2 cells. Higher levels 
of cleaved PARP-1 and caspase 3 appeared after 48 h 
of combined treatment with 100 nM of 17-AAG and 
2 μg/mL of DHMEQ, and this trend was also evident 
when higher doses (4, 8 and 10 μg/mL) of DHMEQ 
were used. Also, the combined treatment markedly 
reduced the expression of inhibitors of apoptosis Bcl-
XL, XIAP and cIAP-2, when compared to the effect 
observed with either agent alone (Fig.3).
DISCUSSION
After promising preclinical studies of 17-AAG in vari-
ous cancer cell lines and xenograft models [12,28-30], 
single agent clinical studies of this compound had 
limited success [14,29]. On the other hand, studies of 
17-AAG in combination with other anticancer drugs 
showed more clinical benefit for cancer patients, despite 
drawbacks such as low water solubility and high hepa-
totoxicity, which could be addressed in the future by 
Fig. 1. Cell viability and synergy 
achieved by the combination of 17-
AAG and DHMEQ in KTC2 cells 
and primary thyrocytes. Cells were 
treated with different concentrations 
of single or both drugs, and viabilities 
were determined by the WST-based 
assay as explained in the Materials and 
Methods. A, B – viability of KTC2 cells 
treated with the indicated concentra-
tions of 17-AAG and DHMEQ for 24 h 
and 48 h, respectively; C, D – viability 
of cultured primary thyrocytes treated 
with the indicated concentrations of 
17-AAG and DHMEQ for 24 h and 
48 h, respectively. 17-AAG – 17-allyl-
amino-17-demethoxygeldanamycin; 
DHMEQ – dehydroxymethylepoxy-
quinomicin; Bars, mean±SD from 
three replicates.
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implementation of nanomaterials-based drug delivery 
carriers [14]. However, more studies in various types of 
malignant tumors are needed to assess the real clinical 
potential of this Hsp90 inhibitor, as well as to identify 
other agents capable of improving its anticancer ef-
fects. DHMEQ, an NF-κB inhibitor, was shown to be 
a potent chemo- and immunosensitizing agent which, 
in combination with cytotoxic therapeutics resulted 
in significant reversal of resistance and tumor cell 
death in various tumors, including anaplastic thyroid 
carcinoma [20,31-36]. To our knowledge, no studies 
of the joint effect of these two compounds in cancer 
cells have been conducted so far.
In the present study, we analyzed the effects of the 
combined treatment of 17-AAG and DHMEQ in hu-
man anaplastic thyroid carcinoma cell line KTC2, as 
compared to the effect of either agent alone. Consistent 
with previous studies, both DHMEQ and 17-AAG 
alone displayed a cytotoxic effect on 
thyroid cancer cells [10-12,23,36]. The 
combined treatment, however, already 
after the first 24 h strongly enhanced the 
growth-inhibitory effect compared with 
the single agent treatment. This effect 
was increased even more after 48 h, and 
by 72 h no cells survived. Moreover, we 
observed a synergistic antiprolifera-
tive effect of the combined treatment 
with all 4 dose combinations of the two 
agents. Furthermore, we established that 
the combined treatment of 17-AAG 
and DHMEQ potentiated apoptosis, 
this being probably one of the mecha-
nisms for controlling tumor cell growth. 
Apoptosis induction was confirmed by 
cleavage of some of the characteristic 
indices of apoptosis, such as caspase 3 
(the key executioner of apoptosis) and 
PARP-1 (the main cleavage target of 
caspase 3). Also, the combined treatment 
markedly reduced the expression of the 
antiapoptotic protein Bcl-xL, as well 
as the expression of cIAP-2 and XIAP, 
which are members of the inhibitors of 
apoptosis family (IAPs) and are known 
to be under transcriptional regulation 
of NF-κB [37]. Consistent with previ-
ous studies, in our study the treatment 
Fig. 2. Combination index analysis of 17-AAG/DHMEQ. The 
straight line (additivity line) is the locus of all dose pairs that should 
give the same effect. A dose pair below the line is synergistic, a 
dose pair on the line is additive, a dose pair above the line is an-
tagonistic. 17-AAG was found to potently synergize with DHMEQ 
at 4 indicated dose pairs after 24, 48 and 72 h of treatment. The 
growth-inhibitory effect was measured by the WST-based assay. 
The figure represents the analysis after 24 h of treatment.
Fig. 3. Western blot analysis of the effect of the drugs on changes of pro- and anti-
apoptotic factors. Cells were treated with the indicated concentrations of 17-AAG 
and DHMEQ for 48 h and whole-cell lysates were examined by Western blotting. 
β-actin was used as the loading control. The densitometry results are presented in 
the table below the Western blot. The expression levels of target proteins are nor-
malized to β-actin.
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with 17-AAG alone was not associated with caspase 3 
cleavage nor significant changes of expression of Bcl-XL, 
XIAP and cIAP-2 [11,12] while DHMEQ treatment was 
most probably the result of NF-κB inhibition [22, 23]. 
However, the changes in expression of the apoptotic 
markers were more prominent when the combined 
treatment of 17-AAG and DHMEQ was applied. The 
higher levels of cleaved PARP-1 and caspase 3 appeared 
after 48 h of combined treatment and were evident at 
all dose combinations. While some studies [22,23] 
have reported that the changes in expression level of 
Bcl-XL in ATC cells treated with DHMEQ were not 
as prominent as the suppression of IAPs, we showed 
that the combined treatment markedly reduced the 
expression level of this antiapoptotic protein, which 
was also accompanied by a significant reduction in the 
expression level of XIAP and cIAP-2. Taken together, 
these results are in agreement with other studies report-
ing that DHMEQ can act synergistically with different 
therapeutic agents in promoting apoptosis in various 
cancer cell lines [33,38-41]. In contrast to carcinoma 
cells, in primary thyrocytes the combination treatment 
was accompanied by more than 90% cell survival rate. 
This is in accordance with previous studies in which 
it was reported that cancer cells are significantly more 
sensitive to Hsp90 inhibition than non-transformed 
cells, as reviewed in [5,29], and studies indicating that 
normal thyroid epithelial cells, compared to cancer 
cells, show relative resistance to DHMEQ-induced 
apoptosis [23].
In light of the fact that dose-related toxicities were 
among the drawbacks for a more successful treatment 
with 17-AAG in clinical studies, another interesting 
finding of our study is that potent growth inhibition 
was achieved by using an overall lower dose of 17-AAG 
(when combined with various doses of DHMEQ) 
compared to doses used thus far [10-12,42,43]. This 
might indicate a potential strategy to decrease 17-AAG 
off-site toxicity in in vivo studies, justifying further 
investigations. 
Finally, we would like to emphasize some of the 
limitations of the present study. The first is that the 
study included only one ATC cell line; it would be 
prudent to repeat the experiments on several other 
ATC cell lines. We also did not address the effect of 
17-AAG and DHMEQ on the activity of their targets, 
Hsp90 and NF-κB, respectively, in order to confirm their 
interaction. Since quantitative Western blotting experi-
ments using untested assumptions of proportionality 
for normalization can be misleading (as described in 
[44]), our results of the expression of apoptosis markers 
should be taken with caution when interpreting the 
results related to the effect of the drugs on apoptosis.
CONCLUSION
Herein we provide the first in vitro evidence that the 
combination of Hsp90 and NF-κB inhibitors, 17-AAG 
and DHMEQ respectively, working in a synergistic 
manner, strongly inhibit cancer cell growth and potenti-
ate apoptosis in human anaplastic thyroid carcinoma 
cells. Further in vitro and in vivo studies of the joint 
action of these two compounds are needed in order 
to clarify the underlying mechanisms, as well as to 
provide an estimate of their potential for translational 
applications in anaplastic thyroid carcinoma patients.
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